Thalidomide in dermatology. New indications for an old drug

International Journal of Dermatology

Volumn 36, Issue 12, 1997, Pages 881-887

  Calderon, Perla ^a   Anzilotti, Michele ^a   Phelps, Robert ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOCHROME P450; CYTOKINE; DEXAMETHASONE; GAMMA INTERFERON; INTERLEUKIN 4; MESSENGER RNA; PENTOXIFYLLINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; APHTHOUS STOMATITIS; BEHCET DISEASE; CLINICAL TRIAL; DISCOID LUPUS ERYTHEMATOSUS; DRUG COST; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HELPER CELL; HUMAN; NEUROTOXICITY; NONHUMAN; PHOCOMELIA; PRURIGO; REVIEW; SKIN DISEASE; SKIN LUPUS ERYTHEMATOSUS; TERATOGENICITY;

EID: 0031450175     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.1997.00298.x     Document Type: Review

References (74)

1. McBride W. Thalidomide embryopathy. Teratology 1977; 16: 79-82.
2. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-4085.
3. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965; 6: 303.
4. Thompson C. Thalidomide effective for AIDS related oral ulcers (news). Lancet 1995; 346: 1289.
5. Powell RJ, Gardner Medwin JM. Guidelines for the clinical use and dispensing of thalidomide. Postgrad Med J 1994; 70: 901-904.
6. Ochonisky S, Verroust J, Bastuji-Garin S, et al. Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients. Arch Dermatol 1994; 130: 73-76.
7. Gunzler V. Thalidomide in human immunodeficiency patients. A review of safety considerations. Drug Safety 1992; 7: 117-133.
8. Bielsa I, Teixido J, Ribera M, Ferrandiz C. Erythroderma due to thalidomide: report of two cases. Dermatology 1994; 189(2): 179-181.
9. Barnhill RL, Doll NJ, Millikan LE, Hastings RC. Studies on the antiinflammatory properties of thalidomide. Arch Dermatol Res 1980; 269: 275-280.
10. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699-703.
11. Tramontana JM, Utaipat U, Molloy A, et al. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995; 1: 384-397.
12. Lahdevirta J, Maury CPJ, Teppo A, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with AIDS. Am J Med 1988 85: 289-291.
13. Keenan RJ, Eiras G, Burckart GJ, et al. Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK 506. Transplantation 1991; 52: 908-910.
14. 4 cells in the peripheral blood. Lepr Rev 1992; 63: 5-11.
15. Gad SM, Shannon EJ, Krotoski WA, Hastings RC. Thalidomide induces imbalances in T-lymphocyte subpopulations in the circulating blood of healthy males. Lepr Rev 1985; 56: 35-39.
16. Mshana RN. Hypothesis: erythema nodosum leprosum is precipitated by an imbalance in T-lymphocytes. Lepr Rev 1982; 53: 1-7.
17. Makonkawkeyoon S, Limson-Pobre RNR, Moreira AL, et al. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993; 90: 5974-5978.
18. Poli G, Kinter A, Justement JS, et al. Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci USA 1990; 87: 782-785.
19. Kaplan G, Moreira AL. TNF alpha regulation of HIV-1: biology and therapy. Res Immunol 1994; 145: 685-689.
20. Moreira AL, Sampaio EP, Zmurdinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-1680.
21. Mchugh SM, Rifkin IR, Deighton J, et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995; 99: 160-167.
22. Powrie F, Coffman R. Cytokine regulation of T cell function: potential for therapeutic interventions. Immunol Today 1993; 14: 270-274.
23. Ching LM, Xu ZF, Gummer BH, et al. Effect of thalidomide on tumor necrosis factor production and antitumor activity induced by 5,6-dimethyl-xanthenone-4-acetic acid. Br J Cancer 1995; 72: 339-343.
24. Neubert R, Hinz N, Thiel R, Neubert D. Down regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide. Life Sci 1995-1996; 58: 295-316.
25. Nogueira AC, Neubert R, Felies A, et al. Thalidomide derivatives and the immune system 6. Effects of two derivatives with no obvious teratogenic potency on the pattern of integrins and other surface receptors on blood cells of marmosets. Life Sci 1995-1996; 58: 337-348.
26. Sheskin J, Sagher F. World survey on the use of thalidomide in leprosy reaction. Med Cutan Ibero Lat Am 1975; 3: 81-83.
27. Grinspan D. Significant response of oral aphthosis to thalidomide treatment. J Am Acad Dermatol 1985; 12: 85-90.
28. Revuz J, Guillaume JC, Janier M, et al. Crossover study of thalidomide vs. placebo in severe recurrent aphthous stomatitis. Arch Dermatol 1990; 126: 923-927.
29. Jorizzo JL, Schmalstieg EN, Daniels JC. Thalidomide effects in Behcet's syndrome and pustular vasculitis. Arch Intern Med 1986; 146: 878-881.
30. Gardner-Medwin JM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 1994; 53: 828-832.
31. Hasper M. Chronic cutaneous lupus erythematosus: thalidomide treatment of 11 patients. Arch Dermatol 1983; 119: 812-815.
32. Hasper MF, Klokke AH. Thalidomide in the treatment of chronic discoid lupus erythematosus. Acta Derm Venereol (Stockh) 1982; 62: 321-324.
33. Atra E, Sato E. Treatment of the cutaneous lesions of lupus erythematosus with thalidomide. Clin Exp Rheumatol 1993; 11: 487-493.
34. Holm AL, Bowers KE, McMeekin TO, Gaspari AA. Chronic cutaneous lupus erythematosus treated with thalidomide. Arch Dermatol 1993; 129: 1548-1550.
35. Barba Rubio J, Franco Gonzalez F. Lupus eritematosos discoide y talidomida. Dermatologia Rev Mex 1975; 19: 131.
36. Knop J, Bensmann G, Happle R, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol 1983; 108: 461-466.
37. Londono F. Thalidomide in the treatment of actinic prurigo. Int J Dermatol 1973; 12: 327-328.
38. Lovell CR, Hawk JLM, Calman CD, Magnus IA. Thalidomide in actinic prurigo. Br J Dermatol 1983; 108: 467-471.
39. Guillaume JC, Moulin G, Thierno Dieng M, et al. Crossover study of thalidomide vs placebo in Jessner's lymphocytic infiltration of the skin. Arch Dermatol 1995; 131: 1032-1035.
40. Van den Broek H. Treatment of prurigo nodularis with thalidomide. Arch Dermatol 1980; 116: 571-572.
41. Winkellmann RK, Connolly SM, Doyle JA, Padilha-Goncalves A. Thalidomide treatment of prurigo nodularis. Acta Derm Venereol (Stock) 1984; 64: 412-417.
42. Mattos O. Prurigo nodular de Hyde tratado con talidomida. Bol Div Nac Lepra 1973; 32: 71-77.
43. Naafs B, Faber WR. Thalidomide therapy: an open trial. Int J Dermatol 1985; 24: 131-134.
44. Eravelly J, Waters MFR. Thalidomide in Weber-Christian disease. Lancet 1977; 1: 251.
45. Silva SR, Viana PC, Lugon NV, et al. Thalidomide for the treatment of uremic pruritus: a crossover randomized double blind trial. Nephron 1994; 67: 270-273.
46. Thomas L, Ducros B, Secchi T, et al. Successful treatment of adult Langerhans cell histiocytosis with thalidomide. Report of two cases and literature review. Arch Dermatol 1993; 129: 1261-1264.
47. Perez Alfonso R, Weiss E, Piquero Martin J, et al. Generalized lichen planus with erosive lesions of the penis treated with thalidomide. Report of two cases and review of literature. Med Cutan Ibero Lat Am 1987; 15: 321-326.
48. Carlesimo M, Giustini S, Rossi A, et al. J Am Acad Dermatol 1995; 32.
49. Carlesimo M, Giustini S, Rossi A, et al. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995; 32: 866-869.
50. Hamza M. Behcet's disease, palmoplantar pustulosis and HLA-B27 treatment with thalidomide. Clin Exp Rheumatol 1990; 8: 427.
51. Reddy M, Sorell SJ, Lange M, Grieco MH. Tumor necrosis factor and HIV p24 levels in serum of HIV 1 infected populations. J AIDS 1988; 1: 436.
52. Barbosa Vosgerau JC. Autoimmunity in human immunodeficiency virus infection and the use of thalidomide. Panminerva Med 1994; 36: 1-4.
53. Poli G, Fauci AS. The effect of cytokines and pharmacologic agents on chronic HIV infection. AIDS Res Hum Retroviruses 1992; 8: 191-197.
54. Paterson D, Georghiou P, Allworth A, Kemp R. Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection. Clin Infect Dis 1995; 20: 250-254.
55. Vicente T, Ortega A, Muñoz P, et al. In vitro activity of thalidomide against Mycobacterium Avium Complex (letter). Arch Intern Med 1993; 153: 534.
56. Youle M, Clarbour J, Farthing C, et al. Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. Br Med J 1989; 298: 432.
57. Radeff B, Kuffer R, Samson J. Recurrent aphthous ulcer in patient infected with human immunodeficiency virus: successful treatment with thalidomide. J Am Acad Dermatol 1990; 23: 523-524.
58. Ghigliotti G, Repetto T, Farris A, et al. Thalidomide: treatment of choice for aphthous ulcers in patients seropositive for human immunodeficiency virus. J Am Acad Dermatol 1993; 28: 271-272.
59. Hellman JK, Duke D, Tucker DF. Prolongation of skin homograft survival by thalidomide. Br J Med 1969; 2: 687-689.
60. Faure M, Thivolet J, Gaucherand M. Inhibition of PMN leucocytes chemotaxis by thalidomide. Arch Dermatol Res 1980; 269: 275-280.
61. Mascaro JM, Lecha M, Torras H. Thalidomide in the treatment of recurrent necrotic and giant mucocutaneous aphthae and aphthosis. Arch Dermatol 1979; 115: 636-637.
62. Eisenbud L, Horowitz I, Kay B. Recurrent aphthous stomatitis of Behcet's type: successful treatment with thalidomide. Oral Surg 1987; 64: 289-292.
63. Rasmelaar CG, Boone RM, Kluin-Nelemans HC. Thalidomide of neuro Behcet's syndrome. Br J Dermatol 1986; 115: 367-370.
64. Patey O, Charasz N, Roncayrol AM, et al. Thalidomide et colite ulcereuse dans la maladie de Behcet. Gastroenterol Clin Biol 1989; 13: 110
65. Moisson YF, Janier M, Civatte J. Thalidomide for recurrent erythema multiforme. Br J Dermatol 1992; 126: 92-93.
66. Bahmer FA, Zaun H, Luszpinski P. Thalidomide treatment of recurrent erythema multiforme. Acta Dermatovener 1982; 62: 449-450.
67. Rustin MHA, Gilkes JJH, Robinson TWE. Pyoderma gangrenosum associated with Behcet's disease: treatment with thalidomide. J Am Acad Dermatol 1990; 23: 941-943.
68. Buckley C, Bayoumi AHM, Sarkany I. Pyoderma gangrenosum with severe pharyngeal ulceration. J Royal Soc Med 1968; 83: 590-591.
69. Munro CS, Cox NH. Pyoderma gangrenosum associated with Behcet's syndrome, response to thalidomide. Clin Exp Dermatol 1988; 13: 408-410.
70. Venencie PY, Saurat JH. Pyoderma gangrenosum chez un enfant. Traitement par la thalidomide. Ann Pédiat 1982; 29: 67-69.
71. Naum SM, Molloy PS, Kania RJ, et al. Use of thalidomide in treatment and maintenance of idiopathic esophageal ulcers in HIV positive individuals. Dig Dis Sci 1995; 40: 1147-1148.
72. Berger TG, Hoffman C, Thieberg MO. Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide. J Am Acad Dermatol 1995; 33: 837-838.
73. Torras H, Lecha M, Mascaro JM. Thalidomide treatment of recurrent necrotic giant mucocutaneous aphthae and aphthosis. Arch Dermatol 1985; 118: 875.
74. Kurkcuoglu N, Atakan N, Eksioglu M. Thalidomide in the treatment of recurrent necrotic giant mucocutaneous aphthae. Br J Dermatol 1985; 112: 632.